Cipolla, Melissa

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,853

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 1,674

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,308

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 721

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 572

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 475

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R. M., Gazumyan, A., Martinez, D. R., et al. (2021) · Journal of Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 305

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 275

Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates

Viant, C., Weymar, G. H. J., Escolano, A., Chen, S., Hartweger, H., Cipolla, M., Gazumyan, A., & Nussenzweig, M. C. (2020) · Cell

T-cell and B-cell ImmunologyImmune responses and vaccinations

Cited by 233

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 39

ISG15 deficiency restricts HIV-1 infection

Jurczyszak, D., Manganaro, L., Buta, S., Gruber, C., Martin-Fernandez, M., Taft, J., Patel, R. S., Cipolla, M., Alshammary, H., Mulder, L. C. F., et al. (2022) · PLOS Pathogens

interferon and immune responsesHIV Research and Treatment

Cited by 32